Troglitazone reduces glyoxalase i protein expression in glioma and potentiates the effects of chemotherapeutic agents

6Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite resistance of most gliomas to chemotherapy, approximately 2/3 of oligodendrogliomas show sensitivity to such agents. This sensitivity has been associated with deletions on chromosome 1p alone or in combination with 19q. Higher expression of the enzyme glyoxalase I has been found in oligodendrogliomas with chromosome 1p intact compared to those with a deletion. Higher expression of this enzyme is also associated with tumor chemoresistance in other cancers. The present study tested whether the drug troglitazone would make a glioma cell line more sensitive to chemotherapeutic agents. This drug was chosen because it has been shown to decrease glyoxalase I enzyme activity in cells. Treatment with troglitazone decreased expression of glyoxalase I, and potentiated cell death when used in combination with chemotherapeutic agents. This decrease in glyoxalase I protein may be one mechanism by which this potentiation occurs, and troglitazone may be a candidate for use in glioma therapy. © 2010 Jeffrey Helgager et al.

Cite

CITATION STYLE

APA

Zhuang, Z., Helgager, J., Li, J., Lubensky, I. A., & Lonser, R. (2010). Troglitazone reduces glyoxalase i protein expression in glioma and potentiates the effects of chemotherapeutic agents. Journal of Oncology. https://doi.org/10.1155/2010/373491

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free